FI20000480A0 - Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina - Google Patents

Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Info

Publication number
FI20000480A0
FI20000480A0 FI20000480A FI20000480A FI20000480A0 FI 20000480 A0 FI20000480 A0 FI 20000480A0 FI 20000480 A FI20000480 A FI 20000480A FI 20000480 A FI20000480 A FI 20000480A FI 20000480 A0 FI20000480 A0 FI 20000480A0
Authority
FI
Finland
Prior art keywords
quinoline
antagonists
alpha
naphthalene derivatives
naphthalene
Prior art date
Application number
FI20000480A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Siegfried Wurster
Mia Engstroem
Juha-Matti Savola
Iisa Hoeglund
Jukka Sallinen
Antti Haapalinna
Original Assignee
Orion Yhtymae Oyj
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oyj, Juvantia Pharma Ltd Oy filed Critical Orion Yhtymae Oyj
Priority to FI20000480A priority Critical patent/FI20000480A0/fi
Publication of FI20000480A0 publication Critical patent/FI20000480A0/fi
Priority to RU2002125944/04A priority patent/RU2002125944A/ru
Priority to HU0204458A priority patent/HUP0204458A3/hu
Priority to PCT/FI2001/000203 priority patent/WO2001064645A2/fr
Priority to KR1020027011453A priority patent/KR20020089372A/ko
Priority to EP01913918A priority patent/EP1263733A2/fr
Priority to JP2001563488A priority patent/JP2003525274A/ja
Priority to MXPA02008402A priority patent/MXPA02008402A/es
Priority to BR0108816-5A priority patent/BR0108816A/pt
Priority to EEP200200490A priority patent/EE200200490A/xx
Priority to SK1233-2002A priority patent/SK12332002A3/sk
Priority to IL15109301A priority patent/IL151093A0/xx
Priority to CZ20022880A priority patent/CZ20022880A3/cs
Priority to AU2001239331A priority patent/AU2001239331A1/en
Priority to CNA018059236A priority patent/CN1468224A/zh
Priority to CA002400657A priority patent/CA2400657A1/fr
Priority to PL01357874A priority patent/PL357874A1/xx
Priority to PE2001000208A priority patent/PE20011084A1/es
Priority to ARP010100993A priority patent/AR034249A1/es
Priority to ZA200206956A priority patent/ZA200206956B/en
Priority to NO20024159A priority patent/NO20024159D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
FI20000480A 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina FI20000480A0 (fi)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
PL01357874A PL357874A1 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists
BR0108816-5A BR0108816A (pt) 2000-03-01 2001-02-28 Derivados de quinolina como antagonistas alfa-2
SK1233-2002A SK12332002A3 (sk) 2000-03-01 2001-02-28 Deriváty chinolínu ako alfa 2 antagonisty
PCT/FI2001/000203 WO2001064645A2 (fr) 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2
KR1020027011453A KR20020089372A (ko) 2000-03-01 2001-02-28 알파-2 길항제로서의 퀴놀린 유도체
EP01913918A EP1263733A2 (fr) 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2
JP2001563488A JP2003525274A (ja) 2000-03-01 2001-02-28 α２−アンタゴニストとしてのキノリン誘導体
MXPA02008402A MXPA02008402A (es) 2000-03-01 2001-02-28 Derivados de quinolina como antagonistas alfa-2.
RU2002125944/04A RU2002125944A (ru) 2000-03-01 2001-02-28 Производные хинолина в качестве альфа-2-антагонистов
EEP200200490A EE200200490A (et) 2000-03-01 2001-02-28 Kinoliini derivaadid alfa-2 antagonistidena
HU0204458A HUP0204458A3 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
IL15109301A IL151093A0 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists
CZ20022880A CZ20022880A3 (cs) 2000-03-01 2001-02-28 Deriváty chinolinu jako alfa 2 antagonisté
AU2001239331A AU2001239331A1 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists
CNA018059236A CN1468224A (zh) 2000-03-01 2001-02-28 用作α-2拮抗剂的喹啉衍生物
CA002400657A CA2400657A1 (fr) 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2
ARP010100993A AR034249A1 (es) 2000-03-01 2001-03-01 Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones
PE2001000208A PE20011084A1 (es) 2000-03-01 2001-03-01 Derivados de quinolina como antagonistas alfa-2
ZA200206956A ZA200206956B (en) 2000-03-01 2002-08-29 Derivatives of quinoline as alpha-2 antagonists.
NO20024159A NO20024159D0 (no) 2000-03-01 2002-08-30 Derivater av kinolin som alfa-2 antagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Publications (1)

Publication Number Publication Date
FI20000480A0 true FI20000480A0 (fi) 2000-03-01

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Country Status (21)

Country Link
EP (1) EP1263733A2 (fr)
JP (1) JP2003525274A (fr)
KR (1) KR20020089372A (fr)
CN (1) CN1468224A (fr)
AR (1) AR034249A1 (fr)
AU (1) AU2001239331A1 (fr)
BR (1) BR0108816A (fr)
CA (1) CA2400657A1 (fr)
CZ (1) CZ20022880A3 (fr)
EE (1) EE200200490A (fr)
FI (1) FI20000480A0 (fr)
HU (1) HUP0204458A3 (fr)
IL (1) IL151093A0 (fr)
MX (1) MXPA02008402A (fr)
NO (1) NO20024159D0 (fr)
PE (1) PE20011084A1 (fr)
PL (1) PL357874A1 (fr)
RU (1) RU2002125944A (fr)
SK (1) SK12332002A3 (fr)
WO (1) WO2001064645A2 (fr)
ZA (1) ZA200206956B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628109A (zh) * 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
ATE374773T1 (de) 2002-04-03 2007-10-15 Orion Corp Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
WO2003082825A1 (fr) * 2002-04-03 2003-10-09 Orion Corporation Utilisation de l'antagoniste d'un alfa2-adrenocepteur en cas de maladies du snc
AU2003224482A1 (en) * 2002-04-30 2003-11-17 Korea Research Institute Of Chemical Technology Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004067513A1 (fr) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonistes pour recepteurs alpha-2 adrenergiques
CA2614116A1 (fr) 2005-07-04 2007-01-11 Novo Nordisk A/S Medicaments
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
EP1968961A2 (fr) 2005-12-21 2008-09-17 Decode Genetics EHF Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation
RU2008150485A (ru) * 2006-05-22 2010-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные производные пиразинона для применения в качестве лекарственного средства
US8318927B2 (en) 2006-05-23 2012-11-27 High Point Pharmaceuticals, Llc 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
MX2012006580A (es) * 2009-12-11 2012-09-28 Genecode As Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
CN103524413B (zh) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 氢化吖啶衍生物及其应用
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
WO2015153535A1 (fr) 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Nouveaux inhibiteurs hdmx et leur utilisation dans le traitement du cancer
WO2016135137A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 4-(phénylamino)quinoléine substitués en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135140A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 4-aminoquinazoline en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135139A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 2,3-dihydrocyclopenta[b]quinoléine en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135138A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés d'oxoquinoléine en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
JP2024536926A (ja) * 2021-09-07 2024-10-08 ギズモ セラピューティクス インコーポレイテッド グリコサミノグリカンとのアミロイドペプチド相互作用の阻害剤を含む化合物及び医薬組成物、治療の方法、並びにその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
NO20024159L (no) 2002-08-30
ZA200206956B (en) 2003-12-01
CA2400657A1 (fr) 2001-09-07
AU2001239331A1 (en) 2001-09-12
IL151093A0 (en) 2003-04-10
HUP0204458A3 (en) 2004-07-28
CZ20022880A3 (cs) 2003-06-18
KR20020089372A (ko) 2002-11-29
CN1468224A (zh) 2004-01-14
PL357874A1 (en) 2004-07-26
NO20024159D0 (no) 2002-08-30
AR034249A1 (es) 2004-02-18
PE20011084A1 (es) 2001-10-25
WO2001064645A3 (fr) 2001-12-27
EE200200490A (et) 2003-12-15
HUP0204458A2 (hu) 2003-04-28
MXPA02008402A (es) 2003-10-14
SK12332002A3 (sk) 2003-07-01
RU2002125944A (ru) 2004-02-27
WO2001064645A2 (fr) 2001-09-07
BR0108816A (pt) 2002-12-10
EP1263733A2 (fr) 2002-12-11
JP2003525274A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
FI20000480A0 (fi) Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
ATE503487T1 (de) Myostatin-antagonisten und verwendungen davon
EE200200400A (et) Kortikotropiini vabastava faktori antagonistid
NO20031097L (no) Kinolinderivater
DE60138706D1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
CY2012026I2 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
EE200300071A (et) Kinasoliini derivaadid
NO20003196L (no) Umiddelbart opplösende doseringsformulering
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE60132108D1 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
DE60139571D1 (de) Muscarin-antagonisten
DK1404357T3 (da) Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer
DE50105934D1 (de) Einzugs- und Pflückeinrichtung
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
DK1163264T3 (da) Nye LHRH-antagonister med forbedrede oplöselighedsegenskaber
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
EE200200204A (et) Asendatud bensimidasooli preparaat
DE60138858D1 (de) Kraftstoffschlauch- Anschlussstruktur und Kraftstoffschlauch
NO20031332D0 (no) Arylalkan-sulfonamider med endothelin-antagonistaktivitet
DE60044426D1 (de) Weiterleitungsvorrichtung und -Verfahren
EE200200653A (et) alfa-2,4-disulfofenüül-N-tert-butüülnitrooni uuedpreparaadid
NO20015237L (no) Integrinreseptor-antagonister
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater